My options · Local relief
Just the dryness and discomfort? Local (vaginal) estrogen
Not every menopause symptom needs a whole-body treatment. If your struggle is vaginal dryness, irritation, or discomfort during sex, or when you urinate there’s a targeted, low-risk option many women are never told about.
What it treats
The genitourinary symptoms of menopause (GSM) vaginal dryness, irritation, painful intercourse, and urinary urgency respond best to local hormone therapy. These are vaginal products that work right where the problem is: in the vaginal, vulvar, and pelvic-floor tissues.
Why it’s low-risk
Because so little hormone is absorbed into the bloodstream, local estrogen carries minimal systemic risk and it does not require added progesterone the way systemic estrogen does. The trade-off is that it won’t help hot flashes or night sweats, and it won’t protect your bones, but it is a great option for GSM.
If dryness or discomfort is the whole story, vaginal estrogen therapy is a low-risk path and one often overlooked because its risks are often confused with systemic estrogen.
What’s available in Canada
Local estrogen options include vaginal creams (conjugated estrogen, sold as Premarin; estrone, sold as Estragyn), a vaginal tablet (estradiol, Vagifem), a vaginal ring (estradiol, Estring), a vaginal insert (estradiol, Imvexxy). There is also another vaginal hormonal option called vaginal DHEA (prasterone, Intrarosa).
The reassuring part
Low-dose vaginal estrogen does not increase hormone levels as it has very low absorption into the body. In the available evidence, it has not been shown to increase the risk of breast cancer, heart disease, stroke, blood clots, or gallbladder problems and it’s considered safe for long-term use, even for many women in whom systemic hormone therapy isn’t recommended.
If this sounds like what you need, it’s worth raising specifically with your provider local and systemic therapy are genuinely different decisions.
This article is general information, not medical advice. Menopausal hormone therapy is individualized any decision should be made with your own healthcare provider.
References
- The 2022 Hormone Therapy Position Statement of The North American Menopause Society Advisory Panel. Menopause. 2022 Jul 1;29(7):767-794.
- Yuksel N, Evaniuk D, Huang L, et al. Guideline No. 422a. J Obstet Gynaecol Can. 2021 Oct;43(10):1188-1204.
- Crandall CJ, Hovey KM, Andrews CA, et al. Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the Women’s Health Initiative Observational Study. Menopause. 2018 Jan;25(1):11-20.
Effica’s clinical guides are prepared by our health team and reflect current Canadian and international menopause guidelines. They’re general information, not a substitute for personalized medical advice.